Ravidomycin (AY-25,545), a new antitumor antibiotic.

Abstract

A streptomycete was isolated from a Guatemala soil sample and found to inhibit Grampositive bacteria including mycobacteria. The antibiotic-producing microorganism was characterized, identified as a new species and named Streptomyces ravidus. The antibiotic principle was extracted with organic solvent from the mycelium, isolated in crystalline form and named ravidomycin. Ravidomycin is mainly active against Gram-positive bacteria including mycobacteria. It shows only weak activity against Gram-negative organisms and no activity against fungi. Ravidomycin exhibits potent antitumor activity against P388 lymphocytic leukemia, Colon 38 tumor and CD8F1 mammary tumor. Acute toxicity in mice is low.

• Authors: S N Sehgal, H Czerkawski, A Kudelski, K Pandev, R Saucier, C Vézina
• Journal: The Journal of antibiotics (J Antibiot (Tokyo)) Vol. 36 Issue 4 Pg. 355-61 (Apr 1983) ISSN: 0021-8820 [Print] England
• PMID: 6853365 (Publication Type: Journal Article)

Chemical References

• Aminoglycosides
• Anti-Bacterial Agents
• Antibiotics, Antineoplastic
• ravidomycin

Topics

• Aminoglycosides (isolation & purification, pharmacology)
• Animals
• Anti-Bacterial Agents
• Antibiotics, Antineoplastic (isolation & purification, pharmacology)
• Mice
• Neoplasms, Experimental (drug therapy)
• Streptomyces (cytology, metabolism)